ALDX Q4 2021 Earnings — Aldeyra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALDXAldeyra Therapeutics, Inc.

$318M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$61,271

Operating Income

-$15M

Net Income

-$16M

EPS (Diluted)

$-0.27

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$984,473

Balance Sheet

Total Assets

$233M

Total Liabilities

$27M

Stockholders' Equity

$206M

Cash & Equivalents

$230M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$61,271	$0	—
Operating Income	-$15M	-$10M	-61.6%
Net Income	-$16M	-$11M	-39.5%